Evidence Base
Research supporting the post-craniotomy recovery model and the need for patient-reported outcomes.
The Unmet Need
Post-Craniotomy Quality of Life
Research consistently demonstrates that post-craniotomy patients experience persistent quality of life impairment that is not captured by standard medical follow-up:
- •Zamanipoor Najafabadi et al. (Leiden University Medical Center) conducted systematic reviews showing that meningioma patients report clinically worse health-related quality of life (HRQoL) than healthy controls — and that this impairment persists years after treatment, even when tumor resection is considered successful.
- •Long-term follow-up studies from the same group documented impaired HRQoL and neurocognitive functioning up to 4 years after intervention in intracranial meningioma patients, challenging the assumption that successful surgery equals successful recovery.
- •Craniotomy patients experience a range of cognitive deficits and emotional disturbances that significantly impact quality of life despite advances in surgical technique. These effects are not systematically captured by current follow-up protocols.
The Information and Assessment Gap
- •Qualitative research shows patients feel the amount and quality of information they received was insufficient, particularly regarding post-operative recovery and long-term life issues. Patients report being told their surgery was successful but receiving little guidance on what recovery would actually look like.
- •Perioperative neuropsychological testing is not routinely conducted due to resource constraints, language barriers, and a lack of understanding about its purpose. The result is that cognitive changes go unmeasured for most patients.
- •Cognition and emotional states are associated with HRQoL but are not always routinely measured during the perioperative period. What we do not measure, we cannot treat.
Post-Surgical Emotional Trajectory
The emotional experience of post-craniotomy recovery involves distinct constructs that are well-documented in the literature but poorly measured in clinical practice:
- •Identity disruption following neurological events is well-documented. Patients describe a discontinuity between who they were before surgery and who they are after — a change that is not captured by depression or anxiety screening.
- •Grief responses to acquired neurological changes are distinct from clinical depression. A patient grieving lost cognitive abilities is having a normal, healthy response to real loss — not a psychiatric disorder. But the PHQ-9 cannot distinguish between these.
- •Neurofatigue is a distinct construct from general fatigue or depression-related fatigue. It is neurological in origin, disproportionate to activity level, and resistant to rest. Standard fatigue items on depression screeners cannot differentiate these.
- •The medical-experience gap — the disconnect between clinical assessments and patient-reported experience — is a recognized phenomenon across chronic conditions. In post-craniotomy care, it is particularly acute because successful imaging can coexist with profound subjective impairment.
Limitations of Existing Instruments
Systematic reviews evaluating patient-reported outcome instruments used in neurosurgical populations reveal consistent gaps:
- •COSMIN-based quality assessments of existing HRQoL measures show that no current instrument adequately captures recovery-specific emotional domains in post-craniotomy populations.
- •The PHQ-9 has known limitations in neurological populations where somatic symptoms (fatigue, concentration difficulty, sleep disturbance) overlap with direct effects of the neurological condition or surgery. This leads to inflated depression scores and potential misclassification.
- •General HRQoL instruments (SF-36, EQ-5D) are too broad to guide clinical action in neurosurgical follow-up. They tell you that quality of life is impaired but notwhy or what to do about it.
- •Disease-specific instruments (EORTC QLQ-BN20, FACT-Br) focus on symptoms and disease burden rather than the recovery experience. They are designed for treatment evaluation, not recovery support.
The PCRES addresses these gaps by measuring constructs that are specific to the post-craniotomy recovery experience and actionable in clinical practice. Six of its eight domains show near-zero overlap with depression measures, confirming that it captures distinct constructs.
The Case for a Recovery-Specific Instrument
The argument for the PCRES is not that existing instruments are bad. It is that they were designed for different populations and different questions. The field needs an instrument built specifically for the post-craniotomy recovery experience.
PROMIS Precedent
The NIH invested in building the PROMIS framework of domain-specific item banks precisely because general measures were insufficient. Different conditions require different measurement approaches. Post-craniotomy recovery is no exception.
FDA PRO Guidance
FDA guidance on Patient-Reported Outcome measures recognizes that content validity — measuring what actually matters to patients — is the foundational measurement property. An instrument cannot be valid if it does not ask the right questions.
The PHQ-9 Playbook
The PHQ-9 became the standard depression screener not because it was the most sophisticated instrument available, but because it was free, brief, validated, and actionable. Pfizer funded its development. Spitzer and Kroenke validated it across nearly 10,000 patients between 1999 and 2009. Then they made it free and public domain. Over 560 publications followed.
The PCRES follows the same principles: free, no license required, brief (5–8 minutes), clinically actionable, and on a structured path to validation. The difference is that modern digital infrastructure and AI-assisted analysis allow us to move faster and more transparently.
PCRES Construct Differentiation
Analysis of PCRES domains against existing depression and anxiety measures demonstrates that the PCRES captures distinct constructs:
| PCRES Domain | Depression Overlap | Unique Construct |
|---|---|---|
| A. Identity | Near-zero | Self-continuity after neurological change |
| B. Real-World Cognition | Near-zero | Functional cognition in daily life |
| C. Emotional Regulation | Moderate | Neurologically-driven dysregulation |
| D. Grief & Loss | Near-zero | Grief for lost abilities (not depression) |
| E. Neurofatigue | Low-moderate | Neurological fatigue distinct from depression fatigue |
| F. Social Connection | Near-zero | Withdrawal from neurological cause |
| G. Medical-Experience Gap | Near-zero | Therapeutic alliance & feeling heard |
| H. Hope & Agency | Near-zero | Forward-looking recovery orientation |
Six of eight PCRES domains show near-zero overlap with depression constructs, confirming that the PCRES measures aspects of recovery that depression screeners cannot capture.
Ongoing Research and Validation
The PCRES is on a structured path to full psychometric validation following COSMIN and FDA PRO Guidance standards. The conceptual foundation and item development phases are complete. Content validity assessment is in progress.
See the Validation Roadmap for detailed progress on each phase, and the Get Involved page to learn how clinicians, researchers, and patients can contribute to the validation effort.
References
Zamanipoor Najafabadi AH, Dijkstra M, van Zandvoort MJE, et al. Impaired health-related quality of life of meningioma patients — a systematic review. Neuro-Oncology. 2017;19(7):897-907.
Zamanipoor Najafabadi AH, et al. Health-related quality of life and neurocognitive functioning up to 4 years after intervention in intracranial meningioma patients. Neuro-Oncology. Leiden University Medical Center.
Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA. 1999;282(18):1737-1744.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
US Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009.
Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments. Qual Life Res. 2010;19(4):539-549.
Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007;45(5 Suppl 1):S3-S11.
Whitney E. Still You: Emotional Recovery After Brain Surgery. 2025.